Liza Laws, Author at Labiotech.eu

News and Trends 26 Sep 2022

Australian Agilex Biolabs expands its capacity with new toxicology testing facility

A toxicology facility with more than 10,000 sq ft of laboratory space has opened in Australia and will help Agilex Biolabs expand its capacity to serve the biotech, pharma and animal health industries. After more than 25 years in the industry, Agilex Biolabs says it will now be able to share with an even more […]

September 26, 2022 - 2 minutesmins - By Liza Laws

Cleara Biotech closes $2.5M round for senescence treatment

News and Trends 26 Sep 2022

Surge raises $2.6M in funding for technology and secures exclusive licensing agreement

Surge, a biotech and artificial intelligence innovator that produces technology to decode immune fingerprints, has received $2.6 million in funding. The technology accurately identifies patients at risk before surgery and enables physicians to quickly forecast the risk of postoperative complications. The funding round was co-led by HCVC, a global early-stage fund dedicated to high-potential […]

September 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 26 Sep 2022

Kupando raises €13M in series A funding round led by Remiges Ventures

A company developing agonists that stimulate immune cells today (September 26) announced it has secured €13 million ($12.6 million) in series A funding. Germany-based Kupando develops TLR/47 that stimulate innate immunity for use in oncology and infectious diseases. Kupando says it will use the funds to complete IND-enabling work and to initiate the clinical development […]

September 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Grant awarded to help bring to market an innovative treatment for bone cancer

A grant has been awarded to look into the feasibility of bringing to market a new therapy to treat osteosarcoma that aids bone regeneration with fewer side-effects. The European Research Council gave the Proof of Concept grant to professor Cristina Canal from the Technical University of Catalunya’s (UPC) department of materials science and engineering who […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 23 Sep 2022

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The Oncologic Drugs Advisory Committee (ODAC) has said it does not consider the treatment for patients with relapsed or refractory multiple myeloma (RRMM) favorable in a benefit-risk profile. Oncopeptides AB has been trialing Pepaxto in the […]

September 23, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Study data for glioblastoma treatment confirms safety and tolerability profile

The final results of a phase 1/2 study of a therapy in recurrent glioblastoma multiforme (GBM) have been reported by Australian-based Telix Pharmaceuticals Ltd. The therapy, TLX101 (4-L-[ 131I] iodo-phenylalanine, or 131I-IPA) administered with external beam radiation therapy (EBRT) and the primary objective was to evaluate and test the safety and tolerability profile of the intravenous therapy […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

A U.S.-based biotech yesterday (September 21) reported additional biomarker results for a treatment of type 2 diabetes (T2D) from a phase 1 study. Glyscend Therapeutics, has been looking at orally administered drug GLY-200, which is a gut-restricted therapeutic. The company also received clearance from the U.S. Food and Drug Administration (FDA) on an Investigational New […]

September 22, 2022 - 4 minutesmins - By Liza Laws

News and Trends 21 Sep 2022

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […]

September 21, 2022 - 3 minutesmins - By Liza Laws

Optics11 Life receives €5 million in funding for drug development

News and Trends 21 Sep 2022

Quinten Health closes financing round to advance disease modeling platforms

A financing round to advance disease modeling platforms and virtual twins in real world has been closed by Quinten Health. The company that works in real-world data science, artificial intelligence (AI) and machine learning (ML) for precision care, made the announcement today (September 21). The round is part of the Quinten Group’s €14 million ($13.9 […]

September 21, 2022 - 3 minutesmins - By Liza Laws

ANINA Transforms Ugly veg into Artistic Ready Meal 2 002

News and Trends 21 Sep 2022

Anina – reshaping the future of food by upcycling rejected vegetables

Two industrial design students were so concerned by the huge amounts of perfectly good fresh produce being wasted, they spent two years working on a healthy solution. Esti Brantz and Meydan Levy noticed that fruit and veg was getting tossed in the trash due to cosmetic reasons such as size, shape, color differences, or […]

September 21, 2022 - 5 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

Bioreactor platform launched to support process development for cell and gene therapy

A medical technology company, today announced the launch of a bioreactor platform that supports process development through to commercial manufacturing for the cell and gene therapy (CGT) sector. Terumo Blood and Cell Technologies (Terumo BCT) named its Quantum Flex Cell Expansion System, after identifying the industry’s need for earlier automation to potentially limit additional and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

News and Trends 20 Sep 2022

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

In a deal with a potential value of $110 million over the next five years, CytoReason has announced an extension of its multi-year partnership with Pfizer. Pfizer will make a $20 million equity investment under the terms of the agreement which will give the company the right to use CytoReason’s artificial intelligence (AI) technology and […]

September 20, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Australian Agilex Biolabs expands its capacity with new toxicology testing facility

Surge raises $2.6M in funding for technology and secures exclusive licensing agreement

Kupando raises €13M in series A funding round led by Remiges Ventures

Grant awarded to help bring to market an innovative treatment for bone cancer

Knockback for drug to treat patients with relapsed or refractory multiple myeloma

Study data for glioblastoma treatment confirms safety and tolerability profile

New phase 1 biomarker results reported by Glyscend Therapeutics for diabetes drug

Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn

Quinten Health closes financing round to advance disease modeling platforms

Anina – reshaping the future of food by upcycling rejected vegetables

Bioreactor platform launched to support process development for cell and gene therapy

CytoReason and Pfizer agree deal worth up to $110M for AI drug discovery and development

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Articles by Liza Laws

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!